. Clinicopathological characteristics of steroid receptor positive patients receiving adjuvant endocrine therapy in the western blot verification. RARA expression was evaluated on tumor homogenates from these patients by western blot. *VEGF determination is missing for one patient in each group.
Supplementary Methods

Cell culture
Human BC MCF7 cells and its subline MCF7/LCC2 (referred to as LCC2) were maintained in MEM with phenol red supplemented with 10% fetal bovine serum (FBS) and 1 % each of L-glutamine, penicillin-streptomycin, nonessential amino acids, and sodium pyruvate (Sigma-Aldrich) in a humidified incubator containing 5 % CO 2 at 37 C. The LCC2 cell line was selected for resistance to 1 µM 4-hydroxytamoxifen (4-OHT) (Sigma-Aldrich) as described by Brunner et al 21 . During and 48 h prior to any treatment, cells were cultured in phenol redfree MEM supplemented with 5 % dextran-coated charcoal-treated (DCC) FBS (Hyclone).
Subcellular fractionation and iTRAQ labelling of peptides
Cells were fractionated into DNA-binding (DNAb) and cytosolic fractions using the QProteome nuclear protein kit (Qiagen), according to the manufacturer's instructions. DNAb and cytosolic fractions were acetone precipitated and pellets were dissolved in 1 % SDS, which were diluted to 0.1 % before protein concentration determination with Bio-rad DC protein assay. Triethylammoniumbicarbonat was added to each sample to give a final concentration 0.5 M. Proteins were reduced by adding tris-(2-carboxyethyl)phosphine (TCEP) and alkylated by methyl methanethiosulfonate (MMTS). Trypsin (modified sequence grade, Promega, Madision WI, USA) was added (1:20, trypsin:protein) and the samples were incubated overnight at 37 C. The iTRAQ labelling (reagents, 114, 115, 116, and 117 Applied biosystems, Foster City, CA, USA) was done according to manufacturer's instructions.
Briefly, each iTRAQ reagent was incubated with the protein digest for one hour, after which the samples were pooled and acidified with formic acid. Excess reagent and detergents were removed from the pooled sample using a SCX-cartridge (strata-X-C, Phenomenex, Torrence, CA, USA). Eluates were lyophilized using speed vac.
IPG-IEF of peptides
Narrow range immobilized gradient isoelectric focusing (IPG-IEF) of iTRAQ-labelled tryptic peptide samples was done using pH 3.5-4.5, 24 cm long strips, kindly supplied by GE The IPG strips were put in the focusing tray and application gels containing samples were placed onto the anodic end of the IPG strip, to touch both the strip and the filter paper. The strips were covered with mineral oil and the focusing was performed on an Ettan™ IPGphor™ (GE Healthcare Bio-Sciences AB) with a 75 µA limit per strip. The following focusing program was used: a gradient up to 500 V for 1 h, to 2000 V in 2 h, to 8000 V in 6 h, and holding at 8000 V until 100 kVh had been reached.
Peptides were extracted from the strips by a prototype liquid handling robot, kindly supplied by GE Healthcare Bio-Sciences AB. A plastic device with 72 wells was put onto each strip and 50 µl of MQ was added to each well. After 30 minutes incubation, the liquid was transferred to a 96 well plate and the extraction was repeated 2 more times. The extracted peptides were dried in speed vac and dissolved in 3 % acetonitrile (ACN), 0.1 % formic acid. including only charge state 2 and above. Active exclusion of precursors was on with 1 repeat and release after 0.12 min. Precursor isolation width was set to medium and the function, scan speed was varied based on precursor abundance was activated.
Nano-LC-MALDI MS/MS analysis
Peptide and protein identification
Peptide identification from the MALDI-TOF/TOF data was carried out using the Paragon algorithm in the ProteinPilot 2.0 software package (Applied Biosystems) 46 . Default settings for a 4800 instrument were used (i.e., no manual settings for mass tolerance was given). The following parameters were selected in the analysis method: iTRAQ 4plex peptide labelled as sample type, MMTS as alkylating agent of cysteine, trypsin as digesting enzyme, 4800 as instrument, gel based ID and Urea denaturation as special factors, biological modifications as ID focus, and thorough ID as search effort.
Peptide identification from the Q-TOF data was carried out using the Spectrum Mill Protein Identification software (Agilent). Data was extracted between MH + 600 and 4000 Da (Agilent's definition). Scans with the same precursor m/z  90 sec,  0.05 m/z matching with a minimum of 20 peaks in MS2 were merged. Trypsin was used as digesting enzyme, and parent and daughter ion tolerance was set to 25 and 50 ppm, respectively. MMTS for cysteine and iTRAQ partial-mix (N-term, K) were set as fixed modifications while oxidized methionine was set as variable modification.
All searches were performed against the IPI database (build 3.62) limited to human sequences. False discovery rate (FDR) was calculated by searching the data against a database consisting of both forward and reversed sequences.
Peptide and protein quantification
We used an in house software denoted PQPQ to improve quantitative accuracy by removing outliers and enable quantification of biological replicates 41 . Peptides with < 1 % FDR were used as master peptides for PQPQ giving a score limit of 90 for proteinpilot and 8 for spectrum mill, p-value for correlation = 0.4, preprocess = normalized to equal mean between samples. A minimum of 2 peptides were used for calculation of quantitatively significantly regulated proteins. Note, because sampling of peptides in data-dependent mode for mass spectrometers is stochastic, some proteins will lack peptides to support calculation of p-values among replicates even though the protein ratios are high. (Phenomenex). iTRAQ labelled peptides were separated by IPG-IEF on a pH 3.7-4.9 strip as described above.
4-OHT and fulvestrant proteomics experiment
nLC-MS/MS on Thermo Scientific LTQ Orbitrap Velos
Before analysis on the Thermo Scientific LTQ Orbitrap Velos, peptides were separated using an Agilent 1200 nano-LC system. Samples were trapped on Zorbax 300SB-C18, 5 µm, 5 x 0.3 mm and separated on a NTCC-360/100-5-153 (Nikkyo Technos., Ltd) column using a gradient of A (3% ACN, 0.1% FA) and B (95% ACN, 0.1% FA), ranging from 3 % to 40% B in 90 min with a flow of 0.4 µl/min. The LTQ Orbitrap Velos was operated in data dependent mode, selecting 5 precursors for sequential fragmentation by CID and HCD, and analyzed by the linear iontrap and orbitrap, respectively. The survey scan was performed in the orbitrap at 30.000 resolution from 300-2000 m/z, using lock mass at m/z 445.120025, with a max injection time of 500 ms and AGC set to 1 x 10 6 ions. For generation of HCD fragmentation spectra, a max ion injection time of 500 ms and AGC of 5 x 10 4 were used before fragmentation at 37.5% normalized collision energy, 30 ms activation time. For FTMS MSn spectra, normal mass range was used, centroiding the data at 7500 resolution. Peptides for CID were accumulated for a max ion injection time of 200 ms and AGC of 3 x 10 4 , fragmented with 35% collision energy, wideband activation on, activation q 0.25, activation time 10 ms before analysis at normal scan rate and mass range in the linear iontrap. Precursors were isolated with a width of 2 m/z and put on the exclusion list for 60 s. Single and unassigned charge states were rejected from precursor selection.
Peptide and protein identification
Proteome discoverer 1.3 with sequest-percolator was used for protein identification. Precursor mass tolerance was set to 10 ppm and for fragments 0.8 Da and 0.02 Da were used for detection in the linear iontrap and the orbitrap, respectively. Oxidized methionine and phosphorylation on S,T and Y was set as dynamic modifications, and carbamidomethylation, N-terminal 8plex iTRAQ, and lysyl 8plex iTRAQ as fixed modifications. Spectra were matched to ensembl 68 limited to human protein sequences, and results were filtered to 1% FDR.
Quantitative cutoff
In the proteomics data, the mean of the duplicate values for vehicle were used to calculate ratios to ligand treatments. Vehicle replicates was filtered for replicate consistency, based on the ratios between the biological duplicates, by regarding proteins with values outside of 2.58
